Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
复制标题
核心针活检与后续手术样本之间激素受体不一致的乳腺癌患者的临床病理特征和疾病结果
DOI：
10.1245/s10434-019-07480-y
复制
发表时间：
2019-05
影响因子：
3.7
通讯作者：
Kunwei Shen
中科院分区：
文献类型：
--
作者：
Siji Zhu;Jiayi Wu;Ou Huang;Jianrong He;Li Zhu;Yafen Li;Weiguo Chen;Xiaochun Fei;Xiaosong Chen;Kunwei Shen
研究背景对于空芯针穿刺活检（CNB）和随后的手术样本（FSS）之间激素受体（HR）状态不一致的患者，如何处理的数据有限。本研究旨在评估这些HR不一致patients. Patients and MethodsInvasive breast cancer patients with paired HR between CNB and FSS进行回顾性分析，分为三组：HR阳性，HR阴性，HR不一致。患者的特点，治疗决策，和疾病的结果进行了比较上述groups.ResultsA共1710例（1233 HR阳性，417 HR阴性，60 HR不一致的患者）。与HR阳性组相比，HR不一致组的人表皮生长因子受体2阳性率更高（P <0.001），Ki 67水平更高（P = 0.001）。HR不一致组和HR阴性组接受辅助化疗的比例分别为95.0%和93.8%，明显高于HR阳性组（66.7%，P <0.001）。在60例HR不一致患者中，34例（56.7%）接受了辅助内分泌治疗。HR不一致组5年无病生存率（DFS）为90.4%，与HR阳性组（87.0%，P = 0.653）和HR阴性组（83.2%，P = 0.522）比较差异无统计学意义。对于HR不一致的患者，接受辅助内分泌治疗或未接受内分泌治疗的患者的DFS无差异（P = 0.259）。结论HR不一致的患者与HR阴性患者相比，具有相似的肿瘤特征，辅助化疗治疗和DFS。内分泌治疗在这些心率不一致患者中的获益尚不确定，值得进一步临床评价。
BackgroundThere are limited data about how to manage patients with discordant hormonal receptor (HR) status between core needle biopsy (CNB) and following surgical sample (FSS). This study aimed to evaluate clinicopathological features and disease outcome for these HR discordance patients.Patients and MethodsInvasive breast cancer patients with paired HR between CNB and FSS were retrospectively analyzed, being classified into three groups: HR positive, HR negative, and HR discordance. Patient characteristics, treatment decisions, and disease outcome were compared among above groups.ResultsA total of 1710 patients (1233 HR positive, 417 HR negative, and 60 HR discordance patients) were enrolled. Compared with the HR positive group, HR discordance patients were associated with more human epidermal growth factor receptor 2 positivity (P< 0.001) and higher Ki67 level (P= 0.001) tumors. The fraction of patients receiving adjuvant chemotherapy was 95.0% and 93.8% in the HR discordance or HR negative groups, much higher than in the HR positive group (66.7%,P< 0.001). Of 60 HR discordance patients, 34 (56.7%) received adjuvant endocrine therapy. The 5-year disease-free survival (DFS) rate was 90.4% for HR discordant patients, showing no statistical difference compared with HR positive (87.0%,P= 0.653) or HR negative (83.2%,P= 0.522) groups. For HR discordance patients, there was no difference in DFS between patients who received adjuvant endocrine therapy or not (P= 0.259).ConclusionsHR discordance patients had similar tumor characteristics, adjuvant chemotherapy treatment, and DFS compared with HR negative patients. The benefit of endocrine therapy in these HR discordance patients is uncertain and deserves further clinical evaluation.
登录
查看更多内容
DOI：
10.1016/s1043-321x(08)80027-6
发表时间：
2008-04
期刊：
Breast Diseases: A Year Book Quarterly
影响因子：
--
作者：
M. Gilcrease
通讯作者：
M. Gilcrease
影响因子：
3.9
作者：
Lorgis, Veronique;Algros, Marie Paule;Pivot, Xavier
通讯作者：
Pivot, Xavier
影响因子：
50.5
作者：
Aebi, S.;Davidson, T.;Cardoso, F.
通讯作者：
Cardoso, F.
影响因子：
4.6
作者：
M. E. Hammond;Daniel F. Hayes;M. Dowsett;D. C. Allred;K. Hagerty;S. Badve;P. Fitzgibbons;G. Francis
通讯作者：
M. E. Hammond;Daniel F. Hayes;M. Dowsett;D. C. Allred;K. Hagerty;S. Badve;P. Fitzgibbons;G. Francis
影响因子：
--
作者：
Hammond, M. Elizabeth H.;Hayes, Daniel F.;Temin, Sarah
通讯作者：
Temin, Sarah